Peter Blume-Jensen - 14 May 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
President and CEO, Director
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 May 2024
Net transactions value
-$459,114
Form type
4
Filing time
16 May 2024, 18:54:44 UTC
Previous filing
27 Nov 2024
Next filing
16 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $459,114 -54,918 -2.1% $8.36 2,561,894 14 May 2024 Direct F1
holding ACRV Common Stock 317,736 14 May 2024 See Footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2 These securities are held by co-founder and EVP, Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.